Takahashi, Fuyuko
Okada, Hiroshi
Hashimoto, Yoshitaka
Kurogi, Kazushiro
Murata, Hiroaki
Ito, Masato
Fukui, Michiaki
Article History
Received: 22 January 2024
Accepted: 27 August 2024
First Online: 2 September 2024
Competing interests
: Fukui M received grants from Astellas Pharma Inc., Oishi Kenko inc., Abbott Japan Co. Ltd., Daiichi Sankyo Co. Ltd., Eli Lilly, Japan, K.K., Taisho Pharma Co., Ltd., MSD K.K., Nippon Boehringer Ingelheim Co. Ltd., Sanwa Kagagu Kenkyusho CO., Ltd., Nippon Chemiphar Co., Ltd., Ono Pharma Co. Ltd., Kissei Pharma Co. Ltd., Takeda Pharma Co. Ltd., Mitsubishi Tanabe Pharma Corp., Novo Nordisk Pharma Ltd., Kyowa Kirin Co., Ltd., Sanofi K.K., Kowa Pharma Co. Ltd., Sumitomo Dainippon Pharma Co., Ltd., Tejin Pharma Ltd., Yamada Bee Farm, and Johnson & Johnson K.K. Medical Co., and TERUMO CORPORATION. Takahashi F, Okada H, Hashimoto Y, Kurogi K, Murata H, and Ito M had no conflicts of interest to declare.